【摘要】 [目的]探讨AIB1在乳腺癌组织中的表达及其与乳腺癌内分泌治疗耐药及预后的关系。[方法]采用免疫组织化学方法检测120例乳腺癌组织、20例癌旁正常乳腺组织、40例良性乳腺病变组织中AIB1表达情况,并分析乳腺癌AIB1表达与乳腺癌内分泌治疗耐药及预后的关系。[结果]乳腺癌组织中AIB1过表达率(40.00%)显著高于正常乳腺组织(10.00%)和乳腺良性病变组织(15.00%)(P<0.05)。内分泌治疗耐药进展病例AIB1蛋白的阳性表达率明显高于内分泌治疗有效病例(60.00%vs27.00%,P<0.05)。[结论]AIB1高表达与乳腺癌内分泌治疗耐药密切相关,AIB1可以作为独立预测乳腺癌内分泌治疗疗效及预后的一个重要参数。更多还原

【Abstract】 [Purpose] To investigate the expression of nuclear receptor coactivators AIB1 in breast cancer,and the relationship of AIB1 expression with estrogen resistance during endocrine therapy and with prognosis of endocrine therapy. [Methods] The expression of AIB1 including 120 cases with breast cancer,20 cases with normal breast and 40 cases with benign lesion was examined by immunohistochemistry. The relationship of AIB1 expression with estrogen resistance and with prognosis of endocrine therapy was analyzed. [Results] The over expression of AIB1 was 40.00% in breast cancers,which was higher than that in benign lesions(15.00%) and in normal breast tissues(10.00%) with significant difference. The over expression rate of AIB1 in patiente with estrogen resistance (60.00%) was higher than that in the patients without recurrence or metastasis (27.00%)(P<0.05). [Conclusion] Over expression of AIB1 closely correlate to endocrine therapy. AIB1 may be as an independent marker for evaluating the efficacy and prognosis for endocrine therapy.更多还原